Horizon Pharma

FDA in-house review spotlights an issue with one of Horizon's endpoints but notes efficacy for lead drug
FDA in-house review spotlights an issue with one of Horizon's endpoints but notes efficacy for lead drug
Endpoints
FDA
Horizon Pharma
clinical trials
teprotumumab
thyroid eye disease
Flag link:
Horizon Pharma’s Thyroid Eye Disease Treatment Could Become a Blockbuster, Analyst Predicts
Horizon Pharma’s Thyroid Eye Disease Treatment Could Become a Blockbuster, Analyst Predicts
BioSpace
Horizon Pharma
thyroid eye disease
teprotumumab
Flag link:
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Yahoo/Benzinga
Concert Pharmaceuticals
Horizon Pharma
Edwards Lifesciences
Zimmer Biomet
Genfit
Precision Biosciences
Boston Scientific
AbbVie
Alexion
Bristol-Myers Squibb
Baxter
Biomarin
AtriCure
Biogen
Seattle Genetics
IPOs
earnings
Flag link:
After thyroid eye drug scores in PhIII test, Horizon Pharma readies marketing application
After thyroid eye drug scores in PhIII test, Horizon Pharma readies marketing application
Endpoints
thyroid eye disease
Horizon Pharma
teprotumumab
Flag link:
Genentech, Horizon Earn Spots on List of ‘Companies That Care’
Genentech, Horizon Earn Spots on List of ‘Companies That Care’
BioSpace
Genentech
Horizon Pharma
employees
Flag link:
Horizon Pharma Receives Two Additional Patents on Ravicti
Horizon Pharma Receives Two Additional Patents on Ravicti
CP Wire
Horizon Pharma
Ravicti
Flag link:
Horizon Pharma Receives Two Additional Patents on Ravicti
Horizon Pharma
Ravicti
Flag link:
Physicians And Patients Finally Avoiding Horizon's Expensive, Low-Value Pain Drugs Duexis And Vimovo
Physicians And Patients Finally Avoiding Horizon's Expensive, Low-Value Pain Drugs Duexis And Vimovo
Forbes
physicians
patients
Horizon Pharma
drug pricing
vivmo
Duexis
painkillers
Flag link:
Specialty pharmacy scrutiny hits again with state's focus on Horizon meds
Specialty pharmacy scrutiny hits again with state's focus on Horizon meds
Fierce Pharma
specialty pharmacies
Horizon Pharma
Express Scripts
Valeant Pharmaceuticals
Flag link:
Krystexxa shows signs of life as Horizon keeps pushing sales force expansion
Krystexxa shows signs of life as Horizon keeps pushing sales force expansion
Fierce Pharma
Krystexxa
Horizon Pharma
drug reps
gout
Flag link:
Horizon CEO Tim Walbert knows patients because he is one
Horizon CEO Tim Walbert knows patients because he is one
Medical Marketing and Media
Tim Walbert
Horizon Pharma
Pharma CEOs
autoimmune disease
Duexis
patients
Flag link:
Horizon dives into eye treatments with River Visions acquisition
Horizon dives into eye treatments with River Visions acquisition
BioPharma Dive
Horizon Pharma
River Visions
M&A
eye health
Flag link:
Horizon Pharma buys River Vision and its fast-tracked eye med for $145M
Horizon Pharma buys River Vision and its fast-tracked eye med for $145M
Fierce Biotech
Horizon Pharma
River Vision
eye health
teprotumumab
thyroid eye disease
Flag link:
Tapping into the rare disease market
Tapping into the rare disease market
BioPharma Dive
Rare Diseases
Incyte
Horizon Pharma
Lundbeck
Flag link:
Horizon Pharma - Aggressive Acquirer Makes Another Move
Horizon Pharma - Aggressive Acquirer Makes Another Move
Seeking Alpha
Horizon Pharma
M&A
Flag link:
Horizon Buys Rare-Disease Company Raptor for $800 Million
Horizon Buys Rare-Disease Company Raptor for $800 Million
Bloomberg
Horizon Pharma
M&A
Rare Diseases
Raptor Pharmaceutical
Procybi
Quinsair
Flag link:
With new additions, PhRMA opens door to generics drugmaker Teva
With new additions, PhRMA opens door to generics drugmaker Teva
BioPharma Dive
PhRMA
generics
Teva Pharmaceuticals
Alexion
Amag Pharmaceuticals
Horizon Pharma
Jazz Pharmaceuticals
Flag link:
Horizon Pharma Spikes On Earnings Beat; Depomed Rises On Upgrade
Horizon Pharma Spikes On Earnings Beat; Depomed Rises On Upgrade
Investors.com
Horizon Pharma
earnings
Depomed
Flag link:
Horizon expects most sales to come later in the year, precipitating share's slide
Horizon expects most sales to come later in the year, precipitating share's slide
BioPharma Dive
Horizon Pharma
Flag link:
Horizon Pharma Raises CEO Walbert's Pay 10-Fold to $93.4 Million
Horizon Pharma Raises CEO Walbert's Pay 10-Fold to $93.4 Million
Bloomberg
Horizon Pharma
executive pay
Timothy Walbert
Flag link:

Pages